Who are Ceftolozane-tazobactam IV's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ceftolozane-tazobactam-iv.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Ceftolozane-tazobactam IV — Competitive Intelligence Brief

Ceftolozane-tazobactam IV (Ceftolozane-tazobactam IV) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Fifth-generation cephalosporin with beta-lactamase inhibitor. Area: Infectious Disease.

marketed Fifth-generation cephalosporin with beta-lactamase inhibitor Penicillin-binding proteins (PBPs); bacterial beta-lactamases Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

Ceftolozane-tazobactam IV (Ceftolozane-tazobactam IV) — Hamad Medical Corporation. Ceftolozane-tazobactam is a beta-lactam antibiotic combined with a beta-lactamase inhibitor that kills bacteria by inhibiting cell wall synthesis while protecting against enzymatic degradation.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Ceftolozane-tazobactam IV TARGET	Ceftolozane-tazobactam IV	Hamad Medical Corporation	marketed	Fifth-generation cephalosporin with beta-lactamase inhibitor	Penicillin-binding proteins (PBPs); bacterial beta-lactamases

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Fifth-generation cephalosporin with beta-lactamase inhibitor class)

Hamad Medical Corporation · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Ceftolozane-tazobactam IV — Competitive Intelligence Brief. https://druglandscape.com/ci/ceftolozane-tazobactam-iv. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab